China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s KiOmed Pharma SA, securing exclusive development and commercialization rights to KiOmedine One for the treatment of osteoarthritis in mainland China, Macau, and Taiwan. Under the agreement, Hansoh will be responsible for the development, regulatory filing, and commercialization of the drug in these territories.
Financial Terms and Responsibilities
Hansoh will pay KiOmed up to EUR 66 million ($63 million) in upfront and milestone payments, along with two-digit future sales-based royalties. This strategic partnership aims to bring KiOmedine One, a next-generation single injection for osteoarthritis, to patients in need across the specified regions.
KiOmedine One: Drug Overview
KiOmedine One is a new generation single injection for the treatment of knee osteoarthritis, based on the world’s first exclusive non-animal KiOmedine CM-Chitosan. This highly purified polysaccharide is derived from the Agaricus bisporus (Flammulina velutipes) mushroom. Unlike hyaluronic acid, KiOmedine One has a dual mechanism of action, relieving discomfort and other symptoms of osteoarthritis by reducing oxidative stress and enhancing joint lubrication. Clinical studies have shown that a single injection of KiOmedine One significantly reduces pain within two weeks, with a 66% reduction in the Osteoarthritis Index (WOMAC) pain score. The reduction in osteoarthritis symptoms can be sustained for at least six months. The drug was launched in Europe last year.
Future Outlook
The licensing agreement between Hansoh Pharmaceutical and KiOmed Pharma marks a significant step in expanding access to innovative treatments for osteoarthritis. By leveraging Hansoh’s strong presence in the Chinese market, KiOmedine One is poised to address a significant unmet need and improve patient outcomes.-Fineline Info & Tech
